Stage III Rectal Cancer AJCC v8 Clinical Trials

27 clinical trials for Stage III Rectal Cancer AJCC v8 across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Family Communications After Genetic Testing — RECRUITING · NA
• Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial — RECRUITING · PHASE1
• FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery — RECRUITING · PHASE2
• Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer — RECRUITING · PHASE1
• Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment — RECRUITING · PHASE2
• Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers — RECRUITING · NA
• Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer — RECRUITING
• Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer — RECRUITING · PHASE1
• Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer — RECRUITING
• Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment — ACTIVE_NOT_RECRUITING
• TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer — COMPLETED · PHASE1
• Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation — ACTIVE_NOT_RECRUITING · PHASE2
• Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer — ACTIVE_NOT_RECRUITING
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study — COMPLETED · PHASE2
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer — COMPLETED · PHASE1
• Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation — ACTIVE_NOT_RECRUITING · PHASE2
• Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial — TERMINATED
• Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer — TERMINATED · PHASE1
• Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer — WITHDRAWN · PHASE2
• Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer — OTHER · PHASE2
• Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer — TERMINATED · PHASE2

Refine this search